title: Comparison of isepamicin with amikacin for the empirical treatment of febrile neutropenic children with malignancies.
abstract: The efficacy and safety of isepamicin at 7.5 mg/kg i.v. q 12 h was prospectively compared with that of amikacin at the same dose for the treatment of febrile neutropenic children with malignancies. Thirty-nine patients were enrolled in the study; 25 received isepamicin and 14 amikacin. Clinical and bacteriological response rates were 100% for both groups. No adverse events occurred. Median peak serum levels were 19.7 mg/l for isepamicin and 19.20 mg/l for amikacin. Median trough serum levels were 0.72 mg/l for isepamicin and 0.68 mg/l for amikacin. It was concluded that isepamicin was as effective and safe as amikacin for the treatment of febrile neutropenic children with malignancies, and might be used in areas where resistance to other aminoglycosides is a problem.
authors.affiliation: University of Athens Second Department of Pediatrics, P. and A. Kyriakou Children's Hospital, Athens, 11527 Greece.
authors.forename: H C
authors.initials: HC
authors.lastname: Maltezou
authors.forename: M
authors.initials: M
authors.lastname: Baka
authors.forename: N
authors.initials: N
authors.lastname: Gombakis
authors.forename: D E
authors.initials: DE
authors.lastname: Koliouskas
authors.forename: H
authors.initials: H
authors.lastname: Kosmidou
authors.forename: E
authors.initials: E
authors.lastname: Malaka-Zafiriou
authors.forename: D A
authors.initials: DA
authors.lastname: Kafetzis
mesh_terms: D000583:Amikacin / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D064420:Drug-Related Side Effects and Adverse Reactions; D005334:Fever / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D005839:Gentamicins / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy* / Q000382:microbiology; D011897:Random Allocation
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; D000583:Amikacin; C016927:isepamicin